Pharmacological lipid lowering for prevention of cardiovascular disease in older adults

• An increasing number of patients with cardiovascular disease (CVD) are older adults. New treatments have improved survival but also increased demand for prevention. Comorbidities in older adults contribute to low cholesterol, but accumulating data show that dyslipidemia is a risk factor for CVD in older adults. Although numerous studies show that statin treatment reduces CVD mortality and morbidity, few studies have targeted older adults specifically. However, post-hoc analyses of subgroups indicate that older adults may benefit from statin treatment. Risk reduction in secondary prevention is similar across all age groups, and the limited data available in primary prevention suggest that statins may be considered in high-risk older adult patients. However, statin therapy in older adults should be individualized, taking into account factors more common in this group. © 2014 Future Medicine Ltd.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kardiologi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)

Nyckelord

antilipemic agent

atorvastatin

hydroxymethylglutaryl coenzyme A reductase inhibitor

low density lipoprotein cholesterol

mevinolin

placebo

pravastatin

rosuvastatin

simvastatin

body weight

cardiovascular disease

cardiovascular mortality

cholesterol blood level

comorbidity

disease association

drug effect

drug targeting

dyslipidemia

heart protection

high risk patient

human

hypertransaminasemia

kidney failure

life expectancy

lifestyle

muscle disease

muscle necrosis

myalgia

myoglobinuria

myopathy

non insulin dependent diabetes mellitus

patient compliance

patient preference

primary prevention

quality of life

review

rhabdomyolysis

risk factor

risk reduction

secondary prevention

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)